Walleye Capital LLC Takes Position in Chimerix, Inc. (NASDAQ:CMRX)

Walleye Capital LLC purchased a new position in Chimerix, Inc. (NASDAQ:CMRX) in the fourth quarter, Holdings Channel reports. The fund purchased 391,274 shares of the biopharmaceutical company’s stock, valued at approximately $1,362,000.

A number of other hedge funds also recently bought and sold shares of CMRX. Assenagon Asset Management S.A. raised its stake in shares of Chimerix by 154.8% during the 4th quarter. Assenagon Asset Management S.A. now owns 817,739 shares of the biopharmaceutical company’s stock worth $2,846,000 after buying an additional 496,823 shares during the period. Charles Schwab Investment Management Inc. purchased a new stake in Chimerix in the 4th quarter worth $183,000. Rosalind Advisors Inc. acquired a new position in Chimerix during the fourth quarter worth $10,614,000. Palumbo Wealth Management LLC purchased a new position in Chimerix during the fourth quarter valued at $221,000. Finally, Valeo Financial Advisors LLC grew its position in shares of Chimerix by 78.8% in the fourth quarter. Valeo Financial Advisors LLC now owns 146,186 shares of the biopharmaceutical company’s stock valued at $509,000 after purchasing an additional 64,420 shares during the period. Hedge funds and other institutional investors own 45.42% of the company’s stock.

Wall Street Analysts Forecast Growth

CMRX has been the topic of a number of research reports. Jefferies Financial Group reaffirmed a “hold” rating and issued a $8.50 price target (down from $10.00) on shares of Chimerix in a research note on Wednesday, March 5th. StockNews.com initiated coverage on Chimerix in a research note on Wednesday. They issued a “hold” rating on the stock. HC Wainwright reissued a “neutral” rating and issued a $8.55 price objective (down from $11.00) on shares of Chimerix in a research note on Wednesday, March 5th. Finally, Wedbush reaffirmed a “neutral” rating and set a $8.55 target price (up previously from $7.00) on shares of Chimerix in a research note on Wednesday, March 5th.

Insider Activity at Chimerix

In related news, CEO Michael T. Andriole sold 7,370 shares of the business’s stock in a transaction dated Thursday, February 13th. The shares were sold at an average price of $4.52, for a total value of $33,312.40. Following the sale, the chief executive officer now directly owns 609,603 shares in the company, valued at approximately $2,755,405.56. The trade was a 1.19 % decrease in their position. The sale was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this link. Over the last three months, insiders have sold 20,760 shares of company stock worth $91,175. Insiders own 13.10% of the company’s stock.

Chimerix Stock Performance

Shares of Chimerix stock opened at $8.54 on Friday. The business’s 50 day moving average price is $7.39 and its 200 day moving average price is $3.99. The company has a market cap of $801.09 million, a price-to-earnings ratio of -9.09 and a beta of -0.17. Chimerix, Inc. has a one year low of $0.75 and a one year high of $8.55.

Chimerix (NASDAQ:CMRX) last announced its quarterly earnings data on Friday, March 21st. The biopharmaceutical company reported ($0.25) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($0.26) by $0.01. The firm had revenue of $0.06 million during the quarter, compared to analysts’ expectations of $0.31 million. On average, analysts predict that Chimerix, Inc. will post -0.99 EPS for the current fiscal year.

Chimerix Profile

Chimerix, Inc, a biopharmaceutical company, develops medicines to improve and extend the lives of patients facing deadly diseases. Its pipeline products include ONC201 a program that is in Phase 3 clinical trial for treating patients with H3 K27M-mutant diffuse glioma, as well as in Phase 2 clinical trial for the treatment of rare neuroendocrine tumors; and ONC206, an imipridone, Dopamine Receptor D2 (DRD2) antagonist, and caseinolytic protease P (ClpP) agonist, which is in Phase 1 clinical trial for adult and pediatric patients with primary central nervous system tumors.